iStent trabecular micro-bypass stent (Glaukos Corp.) for treatment of primary open-angle glaucoma

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation
iStent trabecular micro-bypass stent (Glaukos Corp.) for treatment of primary open-angle glaucoma. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2013

Authors' conclusions
Glaucoma refers to a group of eye diseases in which vision is lost due to damage of the optic nerve, which carries visual information from the eye to the brain. Glaucoma is estimated to affect 4 million people in the United States, and it is the second leading cause of blindness. Though it is not preventable, available treatments may slow the progression of glaucoma; therefore early detection is important. Treatments for glaucoma may include eye drops, laser surgery, or incisional surgery. The aim of treatment is to reduce the pressure of the fluid in the eye, known as intraocular pressure (IOP), in an attempt to prevent further damage to the optic nerve. There are several different types of glaucoma; the most common type is known as primary open-angle glaucoma (POAG). In patients with POAG, fluid may not drain out of the eye properly, despite no physical blockages being evident.

Final publication URL
The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=14961

Indexing Status
Subject indexing assigned by CRD

MeSH
Glaucoma Drainage Implants; Glaucoma, Open-Angles; Prosthesis Implantation

Language Published
English

Country of organisation
United States

English summary
An English language summary is available.

Address for correspondence
HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com

AccessionNumber
32013000324

Date abstract record published
30/04/2013